Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.51
-0.1800-4.88%
Post-market: 3.50-0.0100-0.28%19:59 EDT
Volume:8.49M
Turnover:30.53M
Market Cap:1.45B
PE:-3.21
High:3.72
Open:3.66
Low:3.51
Close:3.69
52wk High:5.63
52wk Low:1.64
Shares:411.96M
Float Shares:339.00M
Volume Ratio:0.68
T/O Rate:2.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0941
EPS(LYR):-1.0941
ROE:-55.50%
ROA:-27.30%
PB:2.07
PE(LYR):-3.21

Loading ...

Is Iovance Biotherapeutics (IOVA) Offering A Compelling Opportunity After Recent Price Swings?

Simply Wall St.
·
Mar 25

A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference

Simply Wall St.
·
Mar 22

Iovance Biotherapeutics grants 3,400 inducement stock options at USD 3.87 exercise price

Reuters
·
Mar 21

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 21

Iovance director Wendy Yarno to retire from board in June 2026

Reuters
·
Mar 21

Iovance Biotherapeutics (IOVA) Is Up 42.7% After Positive Lifileucel Sarcoma Data And New Trial Plan

Simply Wall St.
·
Mar 11

A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum

Simply Wall St.
·
Mar 09

Iovance Biotherapeutics call volume above normal and directionally bullish

TIPRANKS
·
Mar 07

What's Going On With Iovance Biotherapeutics Stock On Friday?

Benzinga_recent_news
·
Mar 07

UBS Adjusts Iovance Biotherapeutics Price Target to $4 From $2, Maintains Neutral Rating

MT Newswires Live
·
Mar 05

Iovance Biotherapeutics Is Maintained at Neutral by UBS

Dow Jones
·
Mar 05

Iovance Biotherapeutics Inc : UBS Raises Target Price to $4 From $2

THOMSON REUTERS
·
Mar 05

Iovance Biotherapeutics price target raised to $4 from $2 at UBS

TIPRANKS
·
Mar 05

Iovance Biotherapeutics Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Mar 03

Iovance Biotherapeutics to Present at TD Cowen Annual Healthcare Conference and Barclays Global Healthcare Conference

Reuters
·
Feb 26

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire
·
Feb 26

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Feb 26

Stock Track | Iovance Biotherapeutics Soars 12.04% Intraday on Multiple Analyst Upgrades and Target Price Increases

Stock Track
·
Feb 25

Iovance Biotherapeutics price target raised to $4 from $3 at Baird

TIPRANKS
·
Feb 25

Iovance Biotherapeutics Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Feb 25